0001104659-24-069787.txt : 20240607 0001104659-24-069787.hdr.sgml : 20240607 20240607192608 ACCESSION NUMBER: 0001104659-24-069787 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240607 FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GROVES JASON L CENTRAL INDEX KEY: 0001480679 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37809 FILM NUMBER: 241031168 MAIL ADDRESS: STREET 1: C/O MEDIFAST, INC. STREET 2: 3600 CRONDALL LANE CITY: OWINGS MILLS STATE: MD ZIP: 21117 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NeuroBo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001638287 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 472389984 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 545 CONCORD AVENUE STREET 2: SUITE 210 CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: (857) 702-9600 MAIL ADDRESS: STREET 1: 545 CONCORD AVENUE STREET 2: SUITE 210 CITY: CAMBRIDGE STATE: MA ZIP: 02138 FORMER COMPANY: FORMER CONFORMED NAME: Gemphire Therapeutics Inc. DATE OF NAME CHANGE: 20150331 4 1 tm2416741-5_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-06-07 0 0001638287 NeuroBo Pharmaceuticals, Inc. NRBO 0001480679 GROVES JASON L C/O NEUROBO PHARMACEUTICALS, INC. 545 CONCORD AVENUE, SUITE 210 CAMBRIDGE MA 02138 1 0 0 0 0 Common Stock 2024-06-07 4 A 0 5051 0 A 17552 D Represents a grant of restricted stock units ("RSUs") issued to the Reporting Person under the Issuer's 2022 Equity Incentive Plan, which vests on the earlier of June 7, 2025 or the day immediately prior to the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. Per the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Policy"), the Reporting Person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the Reporting Person's retirement or other separation from service with the Issuer or death, whichever is earlier. The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-8 reverse stock split on December 20, 2023. /s/ Phillip D. Torrence, by Power of Attorney 2024-06-07